** Shares of drug developer Arvinas ARVN.O fall 3% to $6.98
** Brokerage Leerink lowers ARVN's PT to $9 from $10; cuts rating to "market perform" from "outperform"
** Leerink cuts ARVN rating due to pending visibility on whether it can unlock "vepdegestrant's fundamental value and create a compelling investment thesis"
** ARVN and Pfizer's PFE.N experimental treatment, vepdegestrant, delayed progression of breast cancer by more than three months compared to AstraZeneca's AZN.L Faslodex in patients with ESR1 mutations
** Commitment from PFE in developing vepdegestrant combinations remains uncertain, and it is unlikely another partnership strategy could materialize - Leerink
** New rating reflects uncertainties on the market opportunity and path forward around vepdegestrant as well as the early stage of the pipeline - brokerage
** ARVN has fallen 62.4% YTD, as of last close
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.